StockData

Immunome vs Whitehawk Therapeutics

IMNM and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMNM and WHWK compare

Immunome is the larger company, worth 11 times as much as Whitehawk Therapeutics ($2.0B against $176M).

Immunome grew revenue faster over the last twelve months (−63.3% versus −100% for Whitehawk Therapeutics).

Whitehawk Therapeutics scores higher on the StockData Score (8 against 7 for Immunome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMNMWHWK
Size and price
Market cap$2.0B$176M
Share price$17.18$3.08
Change, 1 year0.23%43.9%
Change, 5 years1.2%−86.3%
Beta (5Y)1.622.33
Employees17723
StockData Score
Total score78 (better)
Valuation score01 (better)
Growth score00
Performance score11
Health score66
Dividend score00
Valuation
P/S486×–
P/B3.3×1.0× (better)
FCF yield−10.5% (better)−39.5%
Growth
Revenue growth (TTM)−63.3% (better)−100%
Revenue growth, 5Y average–−12.6%
Profitability
Operating margin−5948%–
Net margin−5594%–
FCF margin−5119%–
Return on equity−50.1%−45.0% (better)
Financial health
Debt / equity0.000.00
Current ratio21.68 (better)17.38
Altman Z-score35.70 (better)6.35
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%75.8%
Held by insiders6.4%49.9%
Insider net buying, 12 months−$25.2M−$2.6M (better)
Short interest, % of float15.2%8.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.